Page last updated: 2024-08-24

plerixafor and Diffuse Mixed Small and Large Cell Lymphoma

plerixafor has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 72 studies

Research

Studies (72)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (19.44)	29.6817
2010's	58 (80.56)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bonifazi, F; Bosi, A; Cascavilla, N; Cellini, C; Lanza, F; Laszlo, D; Martino, M; Musto, P; Pezzi, A; Saraceni, F; Tani, M; Zuffa, E	1
Azar, N; Chabannon, C; Farina, L; Glaß, B; Hübel, K; Karlin, L; Kron, A; Kron, F; Le Gouill, S; Milkovich, G; Mohty, M; Noppeney, R; Ostermann, H	1
Bolwell, B; Cheverton, PD; DiPersio, JF; Horwitz, ME; Kaufman, JL; Maziarz, RT; McCarty, JM; Micallef, IN; Nademanee, AP; Stadtmauer, EA; Stiff, PJ; Struijs, M; Vargo, R	1
Glaß, B; Hübel, K; Kron, A; Kron, F; Milkovich, G; Mohty, M; Noppeney, R; Ostermann, H	1
Culligan, DJ; Dong, B; Hay, AE; Lawrie, A; Robinson, N	1
Carlo-Stella, C; Corradini, P; Dodero, A; Farina, L; Guidetti, A; Longoni, P; Montefusco, V; Ravagnani, F; Spina, F	1
Alousi, A; Anderlini, P; Champlin, R; Ciurea, S; de Lima, M; Hosing, C; Kebriaei, P; Khouri, I; Nieto, Y; Popat, U; Qazilbash, M; Rondon, G; Smith, VR	1
Bilgin, YM; Croockewit, A; de Greef, GE; Gahar, RR; Visser, O	1
Bolwell, BJ; DiPersio, JF; Marulkar, S; Maziarz, RT; Micallef, IN; Nademanee, AP; Partisano, AM; Stadtmauer, EA; Stiff, PJ	1
Jantunen, E; Kuittinen, O; Kuittinen, T; Kuitunen, H; Kutila, A; Lehtonen, P; Mäntymaa, P; Mikkola, M; Nihtinen, A; Nousiainen, T; Rimpiläinen, J; Varmavuo, V; Vasala, K	1
Isola, LM; Miller, LK; Shi, PA	1
Bensinger, W; Copelan, E; Costa, L; Devine, S; Dipersio, J; Giralt, S; Hosing, C; Leather, H; Maziarz, R; McCarty, J; Negrin, R; Pazzalia, A; Petersen, FB; Rondelli, D; Schriber, J; Shaughnessy, P; Snyder, E; Soiffer, R	1
Carlo-Stella, C; Corradini, P; Farina, L; Guidetti, A; Longoni, P; Ravagnani, F; Roncari, L; Spina, F	1
Bonferroni, M; Borra, A; Castellino, C; Celeghini, I; Di Marco, C; Fiore, F; Gallamini, A; Ghiglia, A; Grasso, M; Marenchino, D; Mattei, D; Mordini, N; Rapezzi, D; Sorasio, R; Strola, G	1
Gardellini, A; Lanza, F; Laszlo, D; Martino, M	1
Costa, LJ; Dermer, SJ; Kumar, S; Stowell, SA	1
Arabi, A; Bekadja, MA; Bouhass, R; Brahimi, M; Osmani, S; Talhi, S; Yafour, N	1
Beckers, EA; Bilgin, YM; Croockewit, AJ; de Greef, GE; Huisman, C; Kramer, EP; Netelenbos, T; te Boome, LC; Visser, O; Ypma, PF	1
Jantunen, E; Kuittinen, T; Lehtonen, P; Mäntymaa, P; Nihtinen, A; Nousiainen, T; Partanen, A; Pelkonen, J; Penttilä, K; Pyörälä, M; Ropponen, A; Silvennoinen, R; Valtola, J; Varmavuo, V; Vasala, K	1
Bao, M; Guan, Y; Guo, R; Li, X; Wang, Y; Wu, A; Xie, F; Yue, Y; Zhang, C	1
Danylesko, I; Nagler, A; Sareli, R; Shem-Tov, N; Shimoni, A; Varda-Bloom, N; Yerushalmi, R	1
Engert, A; Hartmann, T; Hübel, K; Monsef, I; Skoetz, N	1
Motalkina, MS	1
Craig, MD; Cumpston, A; D'Souza, A; Dhakal, B; Eastwood, D; Esselman, J; Fenske, TS; Hamadani, M; Hari, P; Kanate, AS; Pasquini, MC; Shillingburg, A; Veltri, LW; Watkins, K	1
Jantunen, E; Valtola, J; Varmavuo, V	1
Calandra, G; MacFarland, R; Smith, C; Stewart, DA	1
De Clercq, E	1
Badel, K; Calandra, G; Magalhaes-Silverman, M; McCarthy, P; Micallef, I; Stiff, P; Territo, M; Weisdorf, D	1
DiPersio, JF; Kirkpatrick, P; Uy, GL; Yasothan, U	1
Wagstaff, AJ	1
Badel, K; Bensinger, WI; Bridger, G; Calandra, G; Dehner, C; Dugan, MJ; Gibney, C; Liesveld, J; Maziarz, RT; Nademanee, A	1
Badel, K; Calandra, G; Ehninger, G; Fruehauf, S; Goldschmidt, H; Ho, AD; Hübel, K; Moos, M; Müller, S; Topaly, J	1
Bolwell, BJ; Bridger, G; Calandra, G; DiPersio, JF; Jacobsen, E; Maziarz, RT; McCarty, J; Micallef, IN; Nademanee, A; Stiff, PJ	1
Gaarsdal, E; Hansen, PB	1
Bridger, G; Calandra, G; DiPersio, JF; Maziarz, RT; McCarty, JM; Micallef, IN; Stiff, PJ	1
Fesler, MJ; Kudva, G; Petruska, PJ	1
Choi, HY; Yong, CS; Yoo, BK	1
Jantunen, E; Kuittinen, T; Mahlamäki, E; Nousiainen, T; Penttilä, K; Pyörälä, M	1
Gatesman, ML; Kessans, MR; Kockler, DR	1
Booth, B; Brave, M; Ching Lin, S; Farrell, A; Fourie, J; He, K; Justice, R; Lee, SL; Ocheltree, T; Pazdur, R; Pope Miksinski, S; Saber, H; Tornoe, C; Yuan, W	1
Silva, M; Steinberg, M	1
Basak, GW; Dabrowska-Iwanicka, A; Dybko, J; Hawrylecka, D; Kisiel, E; Knopinska-Posluszny, W; Matuszak, M; Rzepecki, P; Szmigielska-Kaplon, A; Urbaniak-Kujda, D; Werkun, J; Wiktor-Jedrzejczak, W; Wroblewska, W; Zielinska, P	1
Albert, MH; Basara, N; Beier, R; Bogner, C; Christopeit, M; Dressler, S; Ebinger, M; Fresen, MM; Frickhofen, N; Galm, O; Hartwig, R; Heits, F; Hertenstein, B; Hübel, K; Kiehl, M; Kröger, N; Lange, F; Liebler, S; Lordick, F; Rösler, W; Salwender, H; Theurich, S; von Lilienfeld-Toal, M; Wehler, D; Weidmann, E; Weigelt, C; Zander, AR	1
Damon, LE	1
Bolwell, BJ; Bridger, G; DiPersio, JF; Hsu, FJ; Marulkar, S; Maziarz, RT; Micallef, I; Nademanee, AP; Stadtmauer, EA; Stiff, PJ	1
Jantunen, E; Kuittinen, T; Mahlamäki, E; Mäntymaa, P; Nousiainen, T; Pyörälä, M	1
Basak, GW; Basic-Kinda, S; Cegledi, A; Giebel, S; Hübel, K; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Reti, M; Wiktor-Jedrzejczak, W	1
Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W	1
Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Lanza, F; Lemoli, R; Mikala, G; Mohty, M; Selleslag, D; Wiktor-Jedrzejczak, W; Worel, N	1
Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N	1
Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Fresen, MM; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, RM; Mikala, G; Mohty, M; Selleslag, D; Worel, N	1
Kaufman, J; Mahaseth, H	1
Jantunen, E; Juutilainen, A; Kuittinen, T; Mahlamäki, E; Mäntymaa, P; Nousiainen, T; Varmavuo, V	1
Jantunen, E; Kuittinen, T; Mäntymaa, P; Nousiainen, T; Varmavuo, V	2
Carson, KR; DiPersio, JF; Gregory, M; Kymes, SM; Lambert, DL; Pusic, I	1
Jantunen, E; Kuittinen, T; Mäntymaa, P; Nousiainen, T; Valonen, P; Varmavuo, V	1
Ball, ED; Belew, H; Helmons, PJ; Lane, JR; Lor, KW	1
Calandra, G; Gandhi, PJ; Jacobsen, ED; Micallef, IN; Shaughnessy, P; Uberti, J; van Rhee, F	1
Devine, SM	1
Ansell, SM; Buadi, F; Dingli, D; Dispenzieri, A; Gastineau, DA; Gertz, MA; Hayman, SR; Hogan, WJ; Inwards, DJ; Johnston, PB; Kumar, S; Lacy, MQ; Litzow, MR; Micallef, IN; Porrata, LF; Sinha, S; Winters, JL; Wolf, R	1
Carlson, K; Chabannon, C; Douglas, K; Ho, AD; Milone, G; Mohty, M; Ossenkoppele, GJ; Pareja, MO; Russell, N; Shaheen, D; Whitaker, N; Willemsen, A	1
Amico, I; Ancora, F; Bartolozzi, B; Bosi, A; Guidi, S; Iacopino, P; Irrera, G; La Fauci, A; Leotta, S; Martino, M; Milone, G; Nozzoli, C; Poidomani, M; Saccardi, R; Spadaro, A; Tripepi, G	1
Armistead, PM; Brown, PM; Coghill, JM; Essenmacher, A; Gabriel, DA; Goyal, R; Irons, R; Rao, KV; Sarantopoulos, S; Serody, JS; Sharf, A; Shea, TC; Whitley, J; Wood, WA	1
Artz, A; Ball, ED; Berryman, R; Devine, S; Dugan, M; Hsu, FJ; Jacobsen, E; Johns, D; Joyce, R; Maziarz, RT; McCarty, J; McSweeney, P; Micallef, I; Shaughnessy, P; Stiff, P; Uberti, J; Vose, J	1
Angell, J; Bolwell, BJ; Calandra, G; Dipersio, JF; Maziarz, RT; Micallef, IN; Nademanee, AP; Stiff, PJ	1
Badel, K; Calandra, G; Devine, SM; DiPersio, JF; Flomenberg, N; Liesveld, J; Vesole, DH; Weisdorf, D	1
Aglietta, M; Carnevale Schianca, F; Cavalloni, G; Grignani, G; Perissinotto, E	1
Ansell, SA; Gastineau, DA; Holtan, SG; Inwards, DJ; Johnston, PB; Markovic, SN; Micallef, IN; Padley, DJ; Porrata, LF	1
Akay, C; Badel, K; Calandra, G; Freytes, CO; Gazitt, Y	1

Reviews

11 review(s) available for plerixafor and Diffuse Mixed Small and Large Cell Lymphoma

Article	Year
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3 Topics: Benzylamines; Cyclams; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins; Survival Analysis; Transplantation, Autologous	2014
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma. The Cochrane database of systematic reviews, 2015, Oct-20, Issue:10 Topics: Benzylamines; Cyclams; Early Termination of Clinical Trials; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Randomized Controlled Trials as Topic; Time Factors; Transplantation, Autologous	2015
Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma. Expert review of hematology, 2016, Volume: 9, Issue:8 Topics: Antigens, CD34; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Premedication; Treatment Outcome	2016
The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochemical pharmacology, 2009, Jun-01, Volume: 77, Issue:11 Topics: Amino Acid Sequence; Anti-HIV Agents; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; HIV; Humans; Lymphoma, Non-Hodgkin; Molecular Sequence Data; Multiple Myeloma; Protein Conformation; Receptors, CXCR4; Virus Internalization	2009
Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma. Drugs, 2009, Volume: 69, Issue:3 Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Infusions, Subcutaneous; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4	2009
[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication]. Ugeskrift for laeger, 2009, Nov-02, Volume: 171, Issue:45 Topics: Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma	2009
Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:1 Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation	2010
Plerixafor: a peripheral blood stem cell mobilizer. Pharmacotherapy, 2010, Volume: 30, Issue:5 Topics: Animals; Benzylamines; Bone Marrow; Chemokine CXCL12; Contraindications; Cyclams; Drug Interactions; Drug Therapy, Combination; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Off-Label Use; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Salvage Therapy	2010
Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Clinical therapeutics, 2010, Volume: 32, Issue:5 Topics: Animals; Antineoplastic Agents; Benzylamines; Cyclams; Cyclophosphamide; Economics, Pharmaceutical; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4	2010
Mobilization of hematopoietic stem cells into the peripheral blood. Expert review of hematology, 2009, Volume: 2, Issue:6 Topics: Animals; Anti-HIV Agents; Benzylamines; Bone Marrow; Chemokine CXCL12; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Mice; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4	2009
Optimizing stem cell collection through CXCR4 antagonists. Frontiers in bioscience (Scholar edition), 2012, 01-01, Volume: 4, Issue:2 Topics: Animals; Benzylamines; Clinical Trials, Phase III as Topic; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Randomized Controlled Trials as Topic; Receptors, CXCR4	2012

Trials

25 trial(s) available for plerixafor and Diffuse Mixed Small and Large Cell Lymphoma

Article	Year
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:6 Topics: Adolescent; Adult; Aged; Benzylamines; Child; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Longitudinal Studies; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Survival Analysis; Transplantation, Autologous; Young Adult	2018
Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs. Bone marrow transplantation, 2019, Volume: 54, Issue:1 Topics: Adult; Aged; Benzylamines; Blood Component Removal; Costs and Cost Analysis; Cyclams; Female; Germany; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Time Factors	2019
Use of Plerixafor in patients that show failure of peripheral blood stem cell mobilization with G-CSF. Experience of three Dutch centers. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2013, Volume: 48, Issue:2 Topics: Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous	2013
Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:5 Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Biomarkers; Cyclams; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Time Factors; Transplantation, Autologous	2014
Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison. Transfusion, 2015, Volume: 55, Issue:10 Topics: Adult; Aged; Anti-HIV Agents; Autografts; Benzylamines; Cyclams; Disease-Free Survival; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukocytes; Lymphoma, Non-Hodgkin; Male; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Survival Rate	2015
Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study. Acta haematologica, 2016, Volume: 135, Issue:1 Topics: Adult; Aged; Anti-HIV Agents; Autografts; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Receptors, CXCR4	2016
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:1 Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Pharmacokinetics; Receptors, CXCR4; Transplantation, Autologous	2009
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:2 Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cell Count; Cyclams; Drug Therapy, Combination; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4	2009
Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone marrow transplantation, 2010, Volume: 45, Issue:1 Topics: Adult; Aged; Antigens, CD34; Antiviral Agents; Benzylamines; Blood Component Removal; Combined Modality Therapy; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Pilot Projects	2010
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone marrow transplantation, 2010, Volume: 45, Issue:2 Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Cell Count; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Polymerase Chain Reaction; Treatment Outcome	2010
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-01, Volume: 27, Issue:28 Topics: Adult; Aged; Benzylamines; Cyclams; Diarrhea; Double-Blind Method; Female; Granulocyte Colony-Stimulating Factor; Headache; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Infusions, Subcutaneous; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult	2009
Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:12 Topics: Benzylamines; Blood Component Removal; Combined Modality Therapy; Cyclams; Double-Blind Method; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged	2009
Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone marrow transplantation, 2011, Volume: 46, Issue:8 Topics: Adolescent; Adult; Aged; Benzylamines; Blood Component Removal; Child; Child, Preschool; Combined Modality Therapy; Compassionate Use Trials; Cyclams; Female; Germany; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Young Adult	2011
Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:8 Topics: Antigens, CD34; Benzylamines; Blood Platelets; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Platelet Count; Survival Analysis; Transplantation, Autologous	2011
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. American journal of hematology, 2011, Volume: 86, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous	2011
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:2 Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Vidarabine	2012
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone marrow transplantation, 2012, Volume: 47, Issue:8 Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Benzylamines; Blood Component Removal; Child; Cyclams; European Union; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Transplantation, Homologous	2012
Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft co Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2012, Volume: 46, Issue:3 Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous	2012
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1 Topics: Adult; Aged; Algorithms; Benzylamines; Case-Control Studies; Costs and Cost Analysis; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Plasmacytoma; Risk Factors; Time Factors; Transplantation, Autologous	2013
Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica, 2013, Volume: 98, Issue:2 Topics: Adult; Aged; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Treatment Outcome	2013
Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program. Bone marrow transplantation, 2013, Volume: 48, Issue:6 Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Time Factors; Transplantation, Autologous; United States	2013
Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:4 Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; CD4 Lymphocyte Count; Cyclams; Double-Blind Method; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Middle Aged; Placebos; Transplantation, Autologous	2013
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-15, Volume: 22, Issue:6 Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Statistics, Nonparametric	2004
AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4 Topics: Adult; Aged; Benzylamines; Cyclams; Disease-Free Survival; Female; Heterocyclic Compounds; Humans; Lymphocyte Count; Lymphocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome	2007
Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients. Stem cells and development, 2007, Volume: 16, Issue:4 Topics: Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Benzylamines; Cyclams; Dendritic Cells; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neutrophils; Patient Selection; Receptors, CXCR4; Recurrence; Tissue Preservation; Transplantation Conditioning; Treatment Outcome	2007

Other Studies

36 other study(ies) available for plerixafor and Diffuse Mixed Small and Large Cell Lymphoma

Article	Year
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach. American journal of hematology, 2017, Volume: 92, Issue:9 Topics: Benzylamines; Biosimilar Pharmaceuticals; Blood Cell Count; Cyclams; Filgrastim; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Propensity Score; Retrospective Studies	2017
Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis. Bone marrow transplantation, 2018, Volume: 53, Issue:3 Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy; Time Factors; Treatment Failure	2018
A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly. Journal of clinical apheresis, 2013, Volume: 28, Issue:5 Topics: Antigens, CD34; Benzylamines; Blood Component Removal; Body Weight; Cost-Benefit Analysis; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Regression Analysis; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome	2013
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. Leukemia & lymphoma, 2014, Volume: 55, Issue:2 Topics: Adult; Aged; Algorithms; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukocyte Count; Leukocytes, Mononuclear; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Time Factors; Transplantation, Autologous; Young Adult	2014
Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. American journal of hematology, 2013, Volume: 88, Issue:9 Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cell Count; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Time Factors; Transplantation, Autologous; Treatment Outcome	2013
Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma. American journal of hematology, 2013, Volume: 88, Issue:12 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Cell Count; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclams; Double-Blind Method; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Neutropenia; Pain; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Young Adult	2013
Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients. Transfusion, 2014, Volume: 54, Issue:5 Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cell Separation; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Receptors, CXCR4; Retrospective Studies; Transplantation, Autologous; Treatment Outcome	2014
Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor. Transfusion, 2014, Volume: 54, Issue:5 Topics: Antigens, CD34; Benzylamines; Cohort Studies; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Kinetics; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Receptors, CXCR4; Time Factors	2014
Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. Bone marrow transplantation, 2014, Volume: 49, Issue:3 Topics: Adult; Aged; Algorithms; Antigens, CD34; Antineoplastic Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged	2014
Plerixafor: what we still have to learn. Expert opinion on biological therapy, 2015, Volume: 15, Issue:2 Topics: Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Obesity; Overweight; Patient Selection; Transplantation, Autologous	2015
Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma. Cancer control : journal of the Moffitt Cancer Center, 2015, Volume: 22, Issue:1 Topics: Benzylamines; Cyclams; Cyclophosphamide; Data Collection; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphoma, Non-Hodgkin; Multiple Myeloma; Practice Patterns, Physicians'; Thalidomide	2015
Plerixafor in the treatment of progenitor cell mobilization failure: First experience in Algeria. Hematology/oncology and stem cell therapy, 2015, Volume: 8, Issue:2 Topics: Adult; Algeria; Antigens, CD34; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Stem Cell Transplantation; Young Adult	2015
Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor. Transfusion, 2015, Volume: 55, Issue:5 Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Netherlands; Retrospective Studies	2015
Plerixafor may treat intractable post-herpetic neuralgia. Medical hypotheses, 2015, Volume: 85, Issue:4 Topics: Benzylamines; Bone Marrow Cells; Cell Movement; Cyclams; Ganglion Cysts; Herpes Zoster; Heterocyclic Compounds; Humans; Inflammation; Lymphoma, Non-Hodgkin; Models, Theoretical; Multiple Myeloma; Neuralgia; Neuralgia, Postherpetic; Neurons; Spinal Cord; Stem Cell Transplantation; Stem Cells; United States	2015
[Combination of pegfilgrastim and plerixafor as an effective regimen of hematopoietic stem cells mobilization in cancer patients: own experience]. Voprosy onkologii, 2015, Volume: 61, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzylamines; Blood Component Removal; Cyclams; Cyclophosphamide; Dexamethasone; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins	2015
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10 Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Transfusion; Carboplatin; Cyclams; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Young Adult	2016
Plerixafor. Nature reviews. Drug discovery, 2009, Volume: 8, Issue:2 Topics: Animals; Benzylamines; Cyclams; Drug Approval; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Randomized Controlled Trials as Topic; Receptors, CXCR4	2009
Plerixafor and pegylated filgrastim: a case of safe and effective hematopoietic stem cell mobilization. Bone marrow transplantation, 2010, Volume: 45, Issue:8 Topics: Benzylamines; Cyclams; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Recombinant Proteins; Remission Induction	2010
Plerixafor (Mozobil). The Medical letter on drugs and therapeutics, 2010, Apr-05, Volume: 52, Issue:1335 Topics: Antineoplastic Agents; Benzylamines; Combined Modality Therapy; Cyclams; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Transplantation, Autologous	2010
Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients. Bone marrow transplantation, 2011, Volume: 46, Issue:2 Topics: Aged; Antineoplastic Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma	2011
FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology, 2010, Volume: 78, Issue:3-4 Topics: Adult; Aged; Antigens, CD34; Benzylamines; Clinical Trials as Topic; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Placebos; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Receptors, CXCR4; United States; United States Food and Drug Administration	2010
Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. Annals of hematology, 2011, Volume: 90, Issue:5 Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cohort Studies; Compassionate Use Trials; Cyclams; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Poland; Receptors, CXCR4; Retrospective Studies; Transplantation, Autologous; Young Adult	2011
Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. European journal of haematology, 2011, Volume: 86, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Female; Filgrastim; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Receptors, CXCR4; Recombinant Proteins; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome	2011
Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late. Leukemia & lymphoma, 2011, Volume: 52, Issue:9 Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome; Young Adult	2011
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. Bone marrow transplantation, 2012, Volume: 47, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Benzylamines; Body Mass Index; Contraindications; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Obesity; Overweight; Retrospective Studies; Thinness; Young Adult	2012
Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. Annals of hematology, 2012, Volume: 91, Issue:7 Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Chemoprevention; Cyclams; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Kinetics; Leukocyte Count; Leukocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Prognosis; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure	2012
Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor. Transfusion, 2012, Volume: 52, Issue:8 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Component Removal; Combined Modality Therapy; Cyclams; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphocyte Subsets; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Receptors, CXCR4; Retrospective Studies; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Vincristine	2012
Economic evaluation of plerixafor for stem cell mobilization. The American journal of managed care, 2012, Volume: 18, Issue:1 Topics: Benzylamines; Costs and Cost Analysis; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Markov Chains; Outcome Assessment, Health Care	2012
Blood graft composition after plerixafor injection in patients with NHL. European journal of haematology, 2012, Volume: 89, Issue:2 Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Female; Flow Cytometry; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Killer Cells, Natural; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; T-Lymphocytes; Transplantation, Autologous	2012
Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma. Pharmacotherapy, 2012, Volume: 32, Issue:7 Topics: Academic Medical Centers; Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Cyclophosphamide; Drug Therapy, Combination; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Transplantation, Autologous	2012
G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT. Bone marrow transplantation, 2013, Volume: 48, Issue:2 Topics: Benzylamines; Blood Component Removal; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukocyte Count; Leukopenia; Lymphoma, Non-Hodgkin; Multiple Myeloma; Platelet Count; Retrospective Studies; Thrombocytopenia	2013
Toward a more rational policy for autologous hematopoietic stem cell mobilization. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:10 Topics: Antigens, CD34; Benzylamines; Clinical Trials, Phase III as Topic; Cyclams; Drug Combinations; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4; Transplantation, Autologous	2012
Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. Blood transfusion = Trasfusione del sangue, 2013, Volume: 11, Issue:1 Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Benzylamines; Cyclams; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Hodgkin Disease; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation, Autologous	2013
Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT. Bone marrow transplantation, 2013, Volume: 48, Issue:6 Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Autografts; Benzylamines; Costs and Cost Analysis; Cyclams; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged	2013
Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16 Topics: Antigens, CD34; Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4	2005
Molecule of the month. Plerixafor hydrochloride. Drug news & perspectives, 2007, Volume: 20, Issue:8 Topics: Anti-HIV Agents; Benzylamines; Clinical Trials as Topic; Cyclams; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Molecular Structure; Multiple Myeloma; Receptors, CXCR4	2007